From Research at med.fsu.edu Fri Jan 14 08:03:08 2022 From: Research at med.fsu.edu (med-Research) Date: Fri, 14 Jan 2022 13:03:08 +0000 Subject: Weekly Funding Opportunities In-Reply-To: References: <6DC2A4C0-3D65-4163-B78A-D703FAA03763@fsu.edu> Message-ID: FSU Council on Research and Creativity Equipment & Infrastructure Enhancement (EIEG) Program Pre-review deadline: February 14, 2022, 4:59 p.m. Due February 24, 2022. Med-RA deadline to receive draft documents: February 14. Multidisciplinary Support (MDS) Program Pre-review deadline: January 24, 2021, 4:59 p.m. Due February 3, 2022. Med-RA deadline to receive draft documents: January 24. Planning Grant (PG) Program Pre-review deadline: February 7, 2022, 4:59 p.m. Due February 17, 2022. Med-RA deadline to receive draft documents: February 7. Small Grants Program (SGP) Pre-review deadline: February 28, 2022, 4:59 p.m. Due March 10, 2022. Med-RA deadline to receive draft documents: February 28. Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 ? Clinical Trial Optional) The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial. Due February 9, 2022; June 9, 2022; October 8, 2022; February 9, 2023; June 9, 2023; October 10, 2023; February 8, 2024; and June 7, 2024. Med-RA deadline to receive draft documents for February 9, 2022 due date: January 27. Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional) This Funding Opportunity Announcement encourages grant applications to develop and translate medical technologies aimed at reducing disparities in healthcare access and health outcomes. Appropriate medical technologies should be effective, affordable, culturally acceptable, and deliverable to those who need them. Due February 11, 2022; January 26, 2023; and January 26, 2024. Med-RA deadline to receive draft documents for February 11, 2022 due date: January 31. Exploratory/Developmental Bioengineering Research Grants (EBRG) R21 Clinical Trial Not Allowed R21 Clinical Trial Optional The purpose of these engineering-oriented funding opportunity announcements is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility Standard dates apply. Expires January 8, 2025. Med-RA deadline to receive draft documents for February 16, 2022 standard date: February 3. Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed) Several valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this funding opportunity announcement is to announce the availability of funding to demonstrate and enhance the utility of selected Common Fund (https://commonfund.nih.gov/) data sets, including generating hypotheses and catalyzing discoveries. Award recipients are asked to provide feedback on the utility of the Common Fund data resources. Due February 18, 2022. Med-RA deadline to receive draft documents: February 7. Johnson & Johnson QuickFire Challenge: Food Allergy Prevention Johnson & Johnson Innovation LLC and the Healthy Baby Initiative within Janssen Research & Development?s World Without Disease Accelerator in partnership with the Food Allergy Fund, has launched the Food Allergy Prevention QuickFire Challenge. Food allergies are a growing public health problem, and for many affected individuals, food allergy begins early in life and persists as a lifelong condition. However, a growing body of work provides insights into potential pathways to reduce the risk of developing food allergies. For example, research points to a window of opportunity in the early years of a child?s life to reduce the risk of food allergies through the early and ongoing ingestion of allergenic foods; data suggest a healthy gut microbiome plays a critical role in decreasing risk; and progress is being made in identifying recognizable risk factors associated with increased likelihood of developing a food allergy, including atopic dermatitis, antibiotic exposure, C-section delivery, and/or a gut microbiome dysbiosis. Through the challenge, the innovator(s) with the best novel methods, products, or technologies have the potential to receive grant funding from a total pool of $150,000, in increments of $75,000, $50,000, or $25,000; access to the global Johnson & Johnson Innovation ? JLABS network; and mentorship from experts across the Johnson & Johnson Family of Companies. Submissions should aim to address one or more of the following focus areas: * Risk detection including connected devices for both point-of-care and at-home prognostics/diagnostics. * Interventions and treatments including preventive therapeutics and health technologies * Community platforms with the potential to establish connectivity, monitor data, educate the public with a specific focus on socioeconomic disparities, and assist communities Due February 18, 2022. Med-RA deadline to receive draft documents: February 7. FSU GAP Commercialization Investment Program The FSU Office of Commercialization is currently accepting applications for the Spring 2022 GAP Commercialization Investment competition, sponsored by the FSU Office of Research. The FSURF GAP Program is designed to support enhancements of inventions or other original works that have been disclosed to FSU. It funds projects that will quickly improve the odds that current research leads to public availability of a new product or service. Pre-proposal due February 25. Med-RA deadline to receive draft documents: February 14. Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system, or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, orofacial pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA. Due March 2, 2022; June 2, 2022; October 2, 2022; February 2, 2023; June 2, 2023; October 4, 2023; February 2, 2024; June 4, 2024; and October 2, 2024. Med-RA deadline to receive draft documents for March 2, 2022 due date: February 17. Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 / R01 Clinical Trial Optional) R21 R01 The purpose of these Funding Opportunity Announcement (FOAs) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. These FOAs encourage the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to these FOAs. Due March 4, 2022; August 5, 2022; November 15, 2022; March 7, 2023; August 9, 2023; November 15, 2023; March 4, 2024; August 5, 2024; and November 15, 2024. Med-RA deadline to receive draft documents for March 4, 2022 due date: February 21. Spectrum of Alzheimer?s Disease/Alzheimer?s Related Dementias and Age-Related Cognitive Decline (R61 / R01 Clinical Trial Optional) R61: Pilot Studies for the Spectrum of Alzheimer?s Disease/Alzheimer?s Disease-Related Dementias and Age-Related Cognitive Decline Due March 4, 2022; June 17, 2022; October 18, 2022; February 17, 2023; June 19, 2023; October 18, 2023; February 20, 2024; June 18, 2024; and October 18, 2024. R01: Early and Late Stage Clinical Trials for the Spectrum of Alzheimer?s Disease/Alzheimer?s Related Dementias and Age-Related Cognitive Decline Due March 4, 2022; June 5, 2022; October 5, 2022; February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024; and October 5, 2024. The purpose of these Funding Opportunity Announcements is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer?s disease and Alzheimer?s disease-related dementias across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods. Med-RA deadline to receive draft documents for March 4, 2022 due date: February 21. HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21 / R01 ? Clinical Trial Not Allowed) R21 R01 The purpose of these Funding Opportunity Announcements is to develop new, exploratory methods, approaches, and/or tools to apply to existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, and mortality records) that could provide novel insights into the dynamics of opioid and prescription drugs misuse, addiction, recovery, relapse, and recovery to facilitate rapid understanding of the opioid epidemic for prevention and treatment or to develop methods for small area estimation that inform decisions of local (e.g., substate) jurisdictions. They will emphasize approaches that shorten the lags between data capture and data availability so the data is available real-time or near real-time to provide actionable insights, and methods and tools that improve efficiency and practical use of surveillance, clinical or other relevant data that may allow for faster or better localized responses or better allocation of resources to address the opioid epidemic. Due March 10, 2022. Med-RA deadline to receive draft documents: February 28. HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional) R01 The National Institutes of Health (NIH) intends to establish a Harm Reduction Network consisting of several research projects and a single Coordination Center. The goal of this network is to increase our understanding of the effectiveness, implementation, and impact of existing and new harm reduction practices to address the ongoing opioid crisis and substance use disorder more broadly. This FOA seeks applications focused on: (1) developing and testing new harm reduction strategies; (2) examining how to effectively implement new and existing harm reduction strategies; (3) expanding the settings and delivery models through which harm reduction strategies are deployed; and (4) examining the impact of new harm reduction policies implemented at state and local levels. Due March 10, 2022. Med-RA deadline to receive draft documents: February 28. Research on Current Topics in Alzheimer?s Disease and Its Related Dementias (R21 / R01 Clinical Trial Optional) R21 R01 The purpose of these Funding Opportunity Announcements (FOAs) is to invite applications proposing research on current topics in Alzheimer?s disease and its related dementias. Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to these FOAs. Due March 11, 2022; July 8, 2022; November 14, 2022; March 10, 2023; July 10, 2023; November 13, 2023; March 11, 2024; July 9, 2024; and November 12, 2024. Med-RA deadline to receive draft documents for March 11, 2022 due date: February 28. Social disconnection and Suicide Risk in Late Life (R21 / R01 Clinical Trial Optional) R21 R01 The purpose of these FOAs is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. Due March 15, 2022 and October 15, 2022. Med-RA deadline to receive draft documents for March 15, 2022 due date: March 2. Pfizer Oncology Investigator Sponsored Research Qualified researchers are invited to submit investigator-sponsored research (ISR) proposals, according to the guidance and instructions found on the Pfizer ISR portal at www.Pfizer.com/ISR. All proposals must be submitted via the ISR submission portal. An ISR proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for ISR submissions are made by the applicable Pfizer Global Review Committee. A formal notification regarding the status of your application will be sent on or before the posted notification date. Pfizer support will only be extended upon the execution of an ISR agreement. For any questions, please send an email to GlobalMedicalGrants at pfizer.com. A list of Oncology assets available for ISR proposals, including Areas of Interest, are available at https://www.pfizer.com/about/programs-policies/grants/investigator-sponsored-research/oncology. Due March 31, 2022; May 31, 2022; August 31, 2022; and January 5, 2023. Med-RA deadline to receive draft documents for March 31, 2022 due date: March 21. Advancing communication strategies to support future HIV vaccine use (R21 / R01 Clinical Trial Optional) R21 R01 These Funding Opportunity Announcements invite applications for Research Project Grants that will advance novel health communication research designed to inform and support acceptance and uptake of future vaccines that protect against HIV. Research should focus on understanding key drivers for HIV vaccine communication success, communication strategies for engagement of communities placed at greatest risk for acquiring HIV, and/or mitigating the impact and reach of HIV vaccine misinformation. Research applications may leverage HIV vaccine analogs (e.g., COVID-19, HPV, HBV vaccines), so long as they have a primary focus on populations placed at risk for HIV, and/or healthcare settings and providers involved in HIV prevention delivery. Due May 10, 2022. Med-RA deadline to receive draft documents: April 27. NIH S10s: Basic Instrumentation Grant (BIG) Program, High-End Instrumentation (HEI) Grant Program, Shared Instrument Grant (SIG) Program BIG The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single high-priced, specialized, commercially available instrument or an integrated instrumentation system. The BIG Program is limited to institutions that have not received S10 instrumentation funding of $250,001 or greater in any of the preceding 3 Federal fiscal years (FY). Use the following to determine applicable funding periods: * for application due date of June 1, 2022, consider S10 funding in FYs 2019-2021; * for application due date of June 1, 2023, consider S10 funding in FYs 2020-2022; * for application due date of June 3, 2024, consider S10 funding in FYs 2021-2023. The minimum award is $25,000. There is no maximum price limit for the instrument; however, the maximum award is $250,000. Instruments supported include, but are not limited to, basic cell sorters, confocal microscopes, ultramicrotomes, gel imagers, or computer systems. HEI The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is $600,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000. Instruments supported include, but are not limited to, X-ray diffractometers, high throughput robotic screening systems, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, flow cytometers, and biomedical imagers. SIG The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation system. The minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $600,000. Instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, flow cytometers, and biomedical imagers. Due June 1, 2022 (FSU is eligible for BIG in 2022); June 1, 2023; and June 3, 2024. Med-RA deadline to receive draft documents for June 1, 2022 due date: May 18 (due to Memorial Day holiday). Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 / R01 Clinical Trial Not Allowed) R01 R21 The purpose of these Funding Opportunity Announcements is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter their effectiveness and thus those parameters should be rigorously addressed in the application. Standard dates apply. Expires January 8, 2025. Med-RA deadline to receive draft documents for June 5, 2022 standard date: May 23; and June 16 standard date: June 3. Risk and Protective Factors of Family Health and Family Level Interventions (R01 ? Clinical Trial Optional) The purpose of this initiative is to advance the science of minority health and health disparities by supporting research on family health and well-being and resilience. The NIMHD Research Framework recognizes family health, family well-being, and family resilience as critically important areas of research to decrease disparities and promote equity. Standard dates apply. Expires May 8, 2025. Med-RA deadline to receive draft documents for June 5, 2022 standard date: May 23. Lipids in Brain Aging and Alzheimer?s Disease (AD) and its Related Dementias (ADRD) (R01 Clinical Trial Not Allowed) The goal of this Funding Opportunity Announcement is to support research addressing critical knowledge gaps in our understanding of how lipids contribute to vulnerability and resilience to brain aging and Alzheimer?s disease (AD) and its related dementias (ADRD), including research addressing how: 1) lipid droplets affect brain aging and AD, including whether their accumulation is pathological or protective; (2) the periphery interacts with lipids in the aging brain, including whether these could be targets for future biomarkers; (3) APOE and lipid-mediated signaling influence brain aging and AD/ADRD progression; and (4) myelin lipids and their signaling contribute to brain aging and AD/ADRD. Due June 14, 2022. Med-RA deadline to receive draft documents: June 1. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: